Ademuyiwa, F. O., Gao, F., Chen, I., Northfelt, D. W., Wesolowski, R., Arora, M., … Gillanders, W. (2021). Nci 10013-A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC). In Cancer Research (Vol. 81).

Ademuyiwa, Foluso O., Feng Gao, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, et al. “Nci 10013-A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC).” In Cancer Research, Vol. 81, 2021.

Ademuyiwa FO, Gao F, Chen I, Northfelt DW, Wesolowski R, Arora M, et al. Nci 10013-A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC). In: Cancer Research. 2021.

Ademuyiwa, Foluso O., et al. “Nci 10013-A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC).” Cancer Research, vol. 81, no. 4, 2021.

Ademuyiwa FO, Gao F, Chen I, Northfelt DW, Wesolowski R, Arora M, Brufsky A, Dees C, Santa-Maria CA, Connolly RM, Force J, Moreno-Aspitia A, Larson S, Sharon E, Gillanders W. Nci 10013-A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC). Cancer Research. 2021.